Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Angiostatin endostatin gene therapy - Oxford BioMedica

Drug Profile

Angiostatin endostatin gene therapy - Oxford BioMedica

Alternative Names: Angiostatin lentivector gene therapy; EIAV.angiostatin - Oxford bioMedica; EIAV.endostatin - Oxford BioMedica; Endostatin lentivector gene therapy; OXB-201; RetinoStat

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Age-related macular degeneration
  • Discontinued Diabetic retinopathy

Most Recent Events

  • 04 Dec 2017 Angiostatin endostatin gene therapy is still in phase I development in Age-related-macular-degeneration(In the elderly, In adults) in USA (Intravitreous, Injection) (Oxford BioMedica pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(In the elderly, In adults) in USA (Intravitreous, Injection)
  • 10 Oct 2016 Efficacy, adverse events and pharmacokinetics data from a phase I trial in wet Age related macular degeneration released by Oxford Biomedcia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top